Evaluation of CXCL10, CXCL11, CXCL12 and CXCL13 chemokines in serum and cerebrospinal fluid in patients with tick borne encephalitis (TBE).
OBJECTIVE
The aim of the study was to assess the concentration of chemokines: CXCL10, XCL11, CXCL12, CXCL13 in serum and cerebrospinal fluid (CSF) in patients with tick-borne encephalitis (TBE) before and after treatment. We evaluated also the usefulness of these molecules in diagnosis and monitoring of inflammation in TBE.


METHODS
Twenty three patients hospitalized in The Department of Infectious Diseases and Neuroinfections of Medical University in Białystok, Poland were included in the study. Patients were divided into 2 groups: TBE group-patients with confirmed TBE and control group (CG): patients with excluded TBE and other inflammatory diseases of CNS. Concentration of CXCL10/IP-10, CXCL11/I-TAC, CXCL12/SDF-1α, CXCL13/BLC/BCA-1 in serum and CSF were measured with ELISA kits (R&D Systems, USA) according to the protocols.


RESULTS
The analysis of chemokines concentration in TBE patients before treatment and control group using ROC showed that serum CXCL10 and CXCL13 and CSF CXCL10, CXCL11, CXCL12 and CXCL13 differentiate both groups (p<0.05). The analysis of CXCL10, CXCL11, CXCL12 and CXCL13 before and after treatment showed that CXCL10 and CXCL11 in CSF and CXCL13 in serum differentiates both groups with p<0.05.


CONCLUSIONS
Concentration of CSF CXCL10, CXCL11, CXCL12, CXCL13 and serum CXCL10, CXCL13 may be good biomarkers of CNS inflammation caused by TBEV. Moreover concentration of CXCL10 in CSF and CXCL13 in serum may be used as indicators of patients recovery.
Department of Infectious Diseases and Neuroinfections, Medical University of Bialystok, Bialystok, Poland. annamoniuszko@op.pl
J
J
Zajkowska
A
A
Moniuszko-Malinowska
S A
SA
Pancewicz
A
A
Muszyńska-Mazur
M
M
Kondrusik
S
S
Grygorczuk
R
R
Swierzbińska-Pijanowska
J
J
Dunaj
P
P
Czupryna
D000328:Adult; D000368:Aged; D015415:Biomarkers; D002490:Central Nervous System / Q000378:metabolism; D054357:Chemokine CXCL10 / Q000097:blood* / Q000134:cerebrospinal fluid*; D054371:Chemokine CXCL11 / Q000097:blood* / Q000134:cerebrospinal fluid*; D054377:Chemokine CXCL12 / Q000097:blood* / Q000134:cerebrospinal fluid*; D054382:Chemokine CXCL13 / Q000097:blood* / Q000134:cerebrospinal fluid*; D004675:Encephalitis, Tick-Borne / Q000188:drug therapy / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D007249:Inflammation; D008297:Male; D008875:Middle Aged; D011044:Poland; D012680:Sensitivity and Specificity
D015415:Biomarkers; C114753:CXCL10 protein, human; C515202:CXCL11 protein, human; C515255:CXCL12 protein, human; C110663:CXCL13 protein, human; D054357:Chemokine CXCL10; D054371:Chemokine CXCL11; D054377:Chemokine CXCL12; D054382:Chemokine CXCL13